Pharmaceutical Product Monograph: Doripenem for Injection (500 mg)
In the pharmaceutical industry, Doripenem is a parenteral, semi-synthetic Ultra-Broad-Spectrum Carbapenem antibiotic. As a pharmacist and manufacturer, I view this molecule as the “Resistant Gram-Negative Specialist”—it is technically designed with a 1-beta-methyl side chain that provides superior stability against many bacterial enzymes (beta-lactamases) and offers the highest potency in its class against Pseudomonas aeruginosa.
At your WHO-GMP facility in Mumbai, Doripenem 500 mg is a high-value “Reserve” SKU for Critical Care and ICU portfolios. It is used as a “last-line” defense for life-threatening hospital-acquired infections.
Therapeutic Profile: Primary Indications
Doripenem is indicated for the treatment of severe infections caused by susceptible strains of multi-drug resistant (MDR) bacteria.
| Indication | Clinical Context | Technical Rationale |
| Nosocomial Pneumonia | VAP / HAP | Gold Standard: Used for Ventilator-Associated Pneumonia where Pseudomonas or Acinetobacter are suspected. |
| Complicated Intra-abdominal | Peritonitis / Sepsis | Provides absolute coverage against gut anaerobes and resistant Gram-negative rods. |
| Complicated UTI | Pyelonephritis | Effective against ESBL-producing E. coli and Klebsiella that have failed all other therapies. |
| Febrile Neutropenia | Oncology ICU | Used as empirical monotherapy in patients with severely suppressed immune systems and high fever. |
Mechanism: High-Affinity PBP Targeting
Doripenem works by sabotaging the final stages of the bacterial cell wall construction with extreme precision:
Porin Channel Entry: Its small molecular size allows it to penetrate the outer membrane of Gram-negative bacteria via OmpF and OmpC porin channels.
PBP Inactivation: It binds with exceptionally high affinity to Penicillin-Binding Proteins (PBPs), specifically PBP-2 and PBP-3 in Pseudomonas and PBP-1a, 1b, 2, and 3 in E. coli.
Transpeptidation Blockade: It halts the cross-linking of peptidoglycan chains.
Rapid Lysis: Technically, this causes a “catastrophic failure” of the cell wall, leading to rapid bacterial death even at low concentrations.
The Pharmacist’s “Technical Warning”
The “VPA” Interaction: As a pharmacist, I must emphasize that Doripenem must not be used in patients taking Valproic Acid (an anti-seizure med). Carbapenems technically lower VPA blood levels by 60–100% within 24 hours, putting the patient at risk for breakthrough seizures.
The “Slow Infusion” Strategy: To maximize “Time above MIC” (the time the drug is effective), Doripenem is often administered as a 4-hour prolonged infusion. This is technically superior for treating resistant Pseudomonas compared to a standard 1-hour injection.
Renal Adjustment: It is strictly excreted by the kidneys. For patients with a $CrCl < 50 \text{ mL/min}$, the dose must be reduced to 250 mg to avoid central nervous system toxicity.
Seizure Risk: While Doripenem has a lower seizure risk than Imipenem, it can technically still lower the seizure threshold in patients with existing CNS disorders.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Aseptic Lyophilization” USP: On your digital marketplace, highlight your Terminal Sterilization & Lyophilization process. Doripenem is a sensitive molecule; your vacuum-drying process ensures a stable 24-month shelf life.
The “Carbapenem Dedicated Block” USP: This is critical. B2B buyers require proof that your Doripenem is manufactured in a Dedicated, Segregated Carbapenem Facility. This prevents cross-contamination with other beta-lactams, which is a mandatory WHO-GMP technical requirement.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Doripenem 500 mg vials to support your registration in international B2B tenders for tertiary care hospitals and government “Reserve Antibiotic” procurement.